Basal ganglia morphology links the metabolic syndrome and depressive symptoms  by Onyewuenyi, Ikechukwu C. et al.
Physiology & Behavior 123 (2014) 214–222
Contents lists available at ScienceDirect
Physiology & Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /phbBasal ganglia morphology links the metabolic syndrome and
depressive symptomsIkechukwu C. Onyewuenyi a, Matthew F. Muldoon b, Israel C. Christie c, Kirk I. Erickson a, Peter J. Gianaros a,⁎
a Department of Psychology, University of Pittsburgh, 3131 Sennott Square, 210 South Bouquet Street, Pittsburgh, PA 15260, United States
b Heart & Vascular Institute, University of Pittsburgh School of Medicine, Old Engineering Hall, Room 506, Pittsburgh, PA 15260, United States
c MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd., Houston, TX 77030, United States
H I G H L I G H T S
• Pallidal volume associated with the metabolic syndrome and depressive symptoms
• The metabolic syndrome associated with depressive symptoms
• Pallidal volume mediated this association⁎ Corresponding author. Tel.: +1 412 383 5078; fax: +
E-mail address: gianaros@pitt.edu (P.J. Gianaros).
0031-9384 © 2013 The Authors. Published by Elsevier Inc
http://dx.doi.org/10.1016/j.physbeh.2013.09.014a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 April 2013
Received in revised form 7 September 2013
Accepted 25 September 2013
Keywords:
Basal ganglia
Cardiovascular disease
Depression
Metabolic syndromeThe metabolic syndrome (MetS) is a clustering of cardiovascular and cerebrovascular risk factors that are often
comorbid with depressive symptoms. Individual components of the MetS also covary with the morphology of
basal ganglia regions that are altered by depression. However, it remains unknown whether the covariation
between the MetS and depressive symptomatology can be accounted for in part by morphological changes in
the basal ganglia. Accordingly, we tested the hypothesis that increased depressive symptoms among individuals
with the MetS might be statistically mediated by reduced gray matter volume in basal ganglia regions. The
presence of the MetS was determined in 147 middle-aged adults using the criteria of the National Cholesterol
Education Program, Adult Treatment Panel III. Basal ganglia volumes were determined on an a priori basis by
automated segmentation of high-resolution magnetic resonance images. Depressive symptoms were assessed
using the Patient Health Questionnaire. Even after controlling for demographic and other confounding factors,
having the MetS and meeting more MetS criteria covaried with reduced globus pallidus volume. Meeting
more MetS criteria and reduced pallidal volume were also related to depressive symptoms. Moreover, the
MetS-depression association was statistically mediated by pallidal volume. In summary, reduced globus pallidus
volume is a neural correlate of the MetS that may partly account for its association with depressive symptoms.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.1. Introduction
The metabolic syndrome (MetS) refers to a clustering of
cardiovascular and cerebrovascular risk factors within the same
individual. These risk factors include atherogenic dyslipidemia,
elevated blood pressure, central adiposity, hypertriglyceridemia, and
glucose dysregulation. Importantly, the MetS confers risk for cardio-
vascular and cerebrovascular disease morbidity and mortality more so
than the risk conferred by any of its individual components [1–7]. The1 412 383 5458.
.Open access under CC BY-NC-ND liceMetS also confers risk for type 2 diabetes mellitus, as well as associated
impairments in cognitive function and adverse mental health outcomes,
particularly dysphoric mood and major depressive disorder [8–10].
As reviewed below, several lines of evidence suggest that the MetS may
be linked to risk for these diverse health outcomes via alterations in
brain systems that are jointly involved in energy balance, metabolism,
cardiovascular regulation, cognitive processes, and emotional functions
that support hedonic or appetitive behaviors [11–14]. At present,
however, the speciﬁc brain systems that may plausibly link the MetS to
often comorbid health outcomes are incompletely understood [15–17].
Accordingly, a primary goal of the present studywas to examinewhether
the basal ganglia may represent one such system, as there is cumulative
evidence showing that aspects of basal ganglia morphology in particular
relate to individual components and clinical sequelae of the MetS
[18–20], as well as to comorbid health conditions that are speciﬁcally
characterized by depressive symptomatology [21].nse.
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show that individuals who exhibit features and correlates of the MetS
also exhibit morphological changes in the basal ganglia, particularly
reduced tissue volumes. For example, increased adiposity among
otherwise healthy individuals has been linked to volumetric reductions
in the putamen and globus pallidus of the basal ganglia [18,20]. In
extension, individuals with type 2 diabetes mellitus – a condition that is
often consequent to the MetS – also exhibit reduced volumes in the
caudate, putamen, and globus pallidus [18]. Recent work has shown
further that glucose dysregulation covaries with reduced volume in
striatal and pallidal regions [19]. Together, these ﬁndings indicate that
components of the MetS (e.g., adiposity, glucose dysregulation) and
endpoints of the MetS (e.g., type 2 diabetes) associate with morpho-
logical, particularly volumetric, changes in basal ganglia regions.
However, despite such prior associations, there are two questions that
still remain open: (i) does the MetS itself, as opposed to its individual
components, relate to reduced volumes within the basal ganglia,
particularly among people without a clinical condition (e.g., type 2
diabetes)? And (ii), doesmeetingmoreMetS criteria – above and beyond
its adiposity and glucose dysregulation components – relate to reduced
volumes within the basal ganglia in a graded fashion? Findings bearing
on these questions would help to address the issue of whether there is
a neural (volumetric) correlate of the MetS that is not confounded by
the presence of a clinical disorder, whichwould have further implications
for understanding associated variation in and risk for mental health
symptoms and health conditions that are often comorbid with this
syndrome.
More precisely, and as noted above, the neural correlates of the
MetS that may in turn relate to risk for comorbid conditions,
particularly those associated with depressive symptoms, remain
incompletely understood. This is despite prior speculations and
indirect evidence that the MetS and depression may share common
pathophysiological features within the brain [9], with structural or
morphological changes in the basal ganglia being one speciﬁc and
possibly shared feature [22]. In support of this possibility, reduced
tissue volumes within the basal ganglia have been associated with
major depression in postmortem samples [23,24]. Moreover,
previous magnetic resonance imaging (MRI) studies on patients
with major depressive disorder (MDD) have reported volumetric
reductions in striatal and pallidal regions [21,25–28]. Secondly,
case study evidence indicates that selective bilateral lesions to the
globus pallidus result in depressive symptoms and concurrent
weight gain [29]. In view of such ﬁndings and prior work relating
individual MetS components and its clinical consequents to reduced
basal ganglia volumes [18–20], it appears plausible that structural or
morphological aspects of the basal ganglia may relate to the
covariation between the MetS and depressive symptoms.
Accordingly, the present study examined the structural neural
correlates of the MetS, with an a priori focus on anatomically deﬁned
regions of interest (ROIs) in the basal ganglia. Hence, based on prior
associations between MetS components and basal ganglia volumes
[18–20], we predicted that otherwise healthy individuals with the
MetS, aswell as thosemeetingmoreMetS criteria, would show reduced
gray matter volume in basal ganglia ROIs, including the striatum
(nucleus accumbens, putamen, caudate nucleus) and the globus
pallidus, beyond the variance accounted for by demographic and
confounding health-related factors. In addition, insofar as the MetS
often exhibits comorbidity with depression [9], we next examined
whether the presence of the MetS and meeting more MetS criteria
would covary with depressive symptomatology. We predicted that
greater depressive symptoms would be observed in individuals with
the MetS relative to those without the syndrome, and among
individuals meeting an increasing number of MetS criteria. Lastly, we
explored the possibility that volumetric changes in basal ganglia regions
might account for (statistically mediate) any observed association
between the MetS and depressive symptoms.2. Materials and methods
2.1. Participants
Participantswere 155 otherwise healthy adults (78men, 77women;
mean age, 40.7±6.2 SD, range=30–50 years) who were recruited by
massmailings to residents of Allegheny County, PA, USA. Inclusion criteria
included no history of (1) cardiovascular disease (including treatment
for or diagnoses of hypertension, stroke,myocardial infarction, congestive
heart failure, and atrial or ventricular arrhythmias); (2) prior neuro-
surgery or neurological disorder; (3) any current treatment for or self-
reported psychiatric disorder; (4) typical consumption of more than
15 alcoholic beverages perweek; (5) daily use of corticosteroid inhaler;
(6) current use of psychotropic, lipid lowering, or any cardiovascular
medication, including any medication to control blood pressure;
(7) metal implants or exposure; (8) colorblindness; and (9) claus-
trophobia. All participants demonstrated right-handedness, as assessed
by the Edinburgh Handedness Inventory [30]. Women were excluded if
pregnant (as veriﬁed by urine test).
The ethnicity of the sample was Caucasian/White (70.3%), African
American/Black (21.9%), Asian (5.8%), and multiracial or other (1.9%).
We have previously reported on the functional neural correlates of
stressor-evoked baroreﬂex suppression [31] and insulin resistance [32]
among a subset of participants from this study. All participants provided
informed consent prior to completing study protocols, which were
approved by the University of Pittsburgh Institutional Review Board.
All analyses were based on a ﬁnal sample size of 147 participants
(76 men, 71 women). This reduced sample size was due to missing
variables needed to compute MetS criteria (n = 3), missing or poor
quality structural neuroimaging data (n=4), and a score on the Patient
Health Questionnaire (PHQ-9) for one participant that was 3 SD above
the mean of the sample (see below). These excluded participants did
not differ from the remaining sample in age, sex, metabolic factors
studied here or in basal ganglia ROI volumes.
2.2. Assessment of the MetS and its components
Participants arrived for a neuroimaging protocol between 7:00 AM
and 11:00 AM, after an 8-hour fast. This also included abstaining
from exercising and consuming caffeine, alcohol, and tobacco products.
Prior to neuroimaging, participants' seated, resting BP was measured
from the non-dominant arm with an oscillometric device (Critikon
Dinamap 8100, Johnson & Johnson, Tampa, FL). Participants provided 3
BP measures taken 2 min apart after a ~20 min acclimation period,
with the average of the last 2 of the 3 BP readings serving as the resting
systolic (SBP) and diastolic (DBP) blood pressures. Participants' waist
circumference (in inches) was measured at the level of the umbilicus
to the nearest 1/2 in at end expiration. After each participant's height,
weight, and waist circumference were measured, a research nurse
performed blood draws. Procedures to determine fasting serum lipids
and glucose levels were performed in the Department of Primary Care
Laboratory Services (Western Psychiatric Institute and Clinic, University
of Pittsburgh Medical Center). Concentrations of total cholesterol
and triglycerides were measured by a CHOL and triglyceride GPO
reagent, respectively, using an enzymatic, timed-endpoint method on
the SYNCHRON LX System (Beckman Coulter, Inc., Brea, California;
[33–37]. The concentration of high-density lipoprotein (HDL) cholesterol
was measured with a HDLD reagent on the SYNCHRON LX System,
which uses an enzymatic, time-endpoint method to uniquely facilitate
a detergent that solubilizes only the HDL lipoprotein particles (Beckman
Coulter, Inc., Brea, California; [33,36]). Low-density lipoprotein (LDL)
cholesterol concentrations were estimated by using the Friedewald
calculation [38].
The MetS was deﬁned by the criteria of the National Cholesterol
Education Program (NCEP) Adult Treatment Panel III [39,40]. According
to NCEP criteria, the MetS is deﬁned as the presence of three or more
1 The alpha coefﬁcient of the PHQ-9 is important to consider when interpreting our
ﬁndings among an otherwise healthy sample. Hence, themagnitude of this scale's internal
consistency can be expected to inﬂuence the magnitude of any observed covariation
between depressive symptoms and theMetS or basal ganglia volumes. However, we note
that signiﬁcant associations were still observed here, despite the moderate value of this
alpha coefﬁcient of the PHQ-9.
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glucose ≥110 mg/dL; (3) waist circumference ≥102 cm in men
or ≥88 cm in women; (4) SBP ≥130 or DBP ≥85mmHg; (5) serum
HDL cholesterol b40mg/dL in men or b50mg/dL in women. Given our
screening criteria, we adopted a conservative NCEP guideline such
that use of medication for hypertension or hyperglycemia was not
factored into deﬁning the presence of the MetS in this cohort. This
conservative deﬁnition of the MetS ensured that presence of disease
or medication use did not confound our results.
2.3. Magnetic resonance imaging
Imaging data were acquired on a 3Tesla Trio TIMwhole-body scanner
(Siemens, Erlangen, Germany), equippedwith a 12-channel phased-array
head coil. For each participant, we obtained T1-weighted magnetization-
prepared rapid gradient echo (MPRAGE) neuroanatomical images
over 7min 17s by these parameters:ﬁeld of view=256×208mm,matrix
size=256×208mm, time to repetition=2100ms, time-to-inversion=
1100ms, time to echo=3.29ms, and ﬂip angle=8° (192 slices, 1mm
thick, no gap). MPRAGE imageswere used to derive volumetric measures
described below.
2.3.1. Volumetric processing
For the a priori segmentation and volumetric analysis of the left
and right basal ganglia ROIs in line with study hypotheses (i.e., caudate
nucleus, putamen, nucleus accumbens, and globus pallidus), we used
the Oxford University Centre for Functional MRI of the Brain (FMRIB)
Integrated Registration and Segmentation Tool (FIRST) in the FMRIB
Software Library (FSL) version 4.0. FIRST is a semi-automated model-
based subcortical segmentation tool that relies on a Bayesian framework,
as well as shape and appearance models obtained from manually
segmented images provided by the Center for Morphometric Analysis,
Massachusetts General Hospital (Boston, MA). Volumetric labels are
parameterized by a three-dimensional deformation of a surface model
based onmultivariate Gaussian assumptions. Speciﬁcally, FIRST searches
through linear combinations of shape modes of variation for the most
probable shape given the intensity distribution in the T1-weighted
image (for a more detailed description of this method, see [41,42]).
This volumetric processing method runs a two-stage afﬁne regis-
tration to a standard space template (Montreal Neurological Institute
space) with 1 mm resolution using 12 degrees of freedom and a
subcortical mask to exclude voxels outside of subcortical regions. Second,
the caudate nucleus, putamen, nucleus accumbens, and globus pallidus
were segmented with 30, 40, 50, and 40modes of variation, respectively.
Modes of variation were optimized based on a leave-one-out cross-
validation using the training set [41]. Finally, boundary correction
was implemented for each structure to classify boundary voxels as
belonging to the structure or not using a statistical probability threshold
(z score N 3.00; p b 0.001). The volume for each structure was then
measured in mm3. Segmentations from each participant were visibly
checked for any signiﬁcant errors that could have occurred during the
segmentation process (no errorswere noted). The correlations between
left and right hemisphere basal ganglia volumes across the entire
sample were strong (rs ranged from 0.70 to 0.90, psb0.001). Hence, for
volumetric analyses, we used the average of participants' bilateral basal
ganglia ROI volumes to reduce the number of statistical tests and because
no laterality was hypothesized regarding the associations between
the MetS, basal ganglia structures, and depression. Lastly, total brain
volume was determined for each subject by calculating the sum of
gray, white, and cerebrospinal ﬂuid using the automated segmentation
toolbox in FSL version 4.0. All volumemeasures (i.e., basal ganglia ROIs,
total brain volume) were standardized (z-score transformed) to aid
interpretation. All normalized basal ganglia ROI volume values were
normally distributed. Supplemental Fig. 1 illustrates the basal ganglia
ROIs.2.4. Assessment of depressive symptoms
Depressive symptoms were measured with the 9-item Patient
Health Questionnaire (PHQ-9). The questionnaire was designed to
aid in screening for affective disorders in primary care settings [43].
The PHQ-9 compares favorably with structured diagnostic interviews,
particularly for major depressive disorder, (MDD) in both clinical
populations as well as those with coronary heart disease [44–46].
This is in part due to the fact that each item on PHQ-9 assesses the
frequency of depressive symptoms as per the 9 diagnostic criteria for
MDD in Diagnostic and Statistic Manual of Mental Disorder Fourth Edition
(DSM-IV). The PHQ-9 also demonstrates acceptable reliability and
validity as a measure of depression severity [45]. In the present study,
the PHQ-9 displayed acceptable internal consistency (α=0.64).1
Participants reported the frequency of experiencing 9 depressive
symptoms during the past two weeks, ranging from “not at all” (scored
0), “several days” (scored 1), “more than half the days” (scored 2), and
“nearly every day” scored 3. Thus, possible scores on the PHQ-9 were
0–27. For our sample, PHQ-9 scores ranged from 0–6, which suggests
mild depressive symptoms on average (see Table 1). This is consistent
with our screening criteria, which excluded subjects with reported
histories or current experiences of mood related disorders. Based on a
recommended and established PHQ-9 cut-off score ≥10, we excluded
one participant (PHQ-9= 13) in the distribution from all analyses for
possible major depression [45,46] as well as being more than 3 SDs
above the group mean. There was another PHQ-9 outlier score that
was 3 SDs above the group mean (PHQ-9 = 9); however, this score
did not exceed the established clinical PHQ-9 cut-off score cited above.
Hence, this score was winsorized by transforming the data point to 3
SDs from the group mean. This transform improved the normality of
the PHQ-9 distribution, enabling parametric testing.
2.4.1. Long-term test-retest stability of PHQ-9
Test-retest assessment of the PHQ-9 was performed on a subset of
participants (n = 94) from the 155 participants who completed the
PHQ-9 on two occasions, separated by a ~3year delay. These reliability
analyses were performed to determine the stability of PHQ-9. We
found that PHQ-9 scores at Time 1 and Time 2 were signiﬁcantly
correlated (r=0.50, pb0.01), indicating a moderately stable dimension
of individual difference assessed by this depression questionnaire.
Additional analyses determined the stability of the PHQ-9 using SPSS
20 to compute the intra-class correlation coefﬁcient (ICC) with a two-
factor mixed-effects model and type consistency. The PHQ-9 showed
moderate consistency over the 3 years (ICC = 0.59, p b 0.01), which
further suggests the long-term stability of scores on this questionnaire.
2.5. Assessment of covariates
Associations between the MetS, basal ganglia volumes, and depres-
sive symptoms may be accounted for by (or confounded with) several
factors, including age, sex, race (non-white versus white), years of
education, and smoking status (i.e., categorically deﬁned as 0 = non-
smoker, 1=smoker). These factors were treated as covariates. Of note,
all covariateswere chosen a priori based on existing research implicating
them in associationwith theMetS, basal gangliamorphology, or psycho-
logical wellbeing. First, the prevalence of the MetS among U.S. adults is
known to vary by age, sex, and race [47]. Second, education and smoking
habits have been associatedwith the presence of theMetS [48,49]. Third,
consistent with the age-, sex-, and smoking-related differences in the
Table 1
Descriptive characteristics of the sample.
Full sample
(n=147)
Individuals meeting
NCEP MetS criteria
(n= 24)
Individuals not meeting
NCEP MetS criteria
(n= 123)
Age, yrs 40.5± 0.5 40.8± 1.3 40.5± 0.6
Sex, m/f 76/71 12/12 64/59
Smoking status,
never/former/current 97/28/22 14/4/6 83/24/16
Education, yrs 17.2± 0.3 16.8± 0.6 17.3± 0.3
Systolic BP, mmHg⁎ 120.1± 0.8 128.3± 1.8 119.5± 0.9
Diastolic BP, mmHg⁎ 73.4± 0.8 77.9± 2.0 72.5± 0.8
BMI, kg/m2⁎ 27.1± 0.4 32.1± 0.9 26.1± 0.4
Waist, in⁎ 35.6± 0.4 41.2± 0.6 34.5± 0.4
Hip, in⁎ 42.1± 0.5 45.2± 0.7 41.5± 0.5
Triglycerides, mg/dLa⁎ 74.0 (63.0) 147.0 (142.0) 70.0 (41.0)
HDL cholesterol, mg/dL⁎ 49.6± 1.4 37.1± 1.1 52.0± 1.5
Glucose, mg/dLa⁎ 87 (12.0) 96.0 (23.0) 86.0 (12.0)
Verbal IQ 113.8± 0.7 112.2± 2.0 114.2± 0.8
PHQ-9, total score 1.0± 0.1 1.3± 0.4 0.9± 0.1
Basal ganglia gray matter volumes, mm3
Caudate nucleus 6950.1± 69.7 6748.1± 160.6 6989.5± 76.9
Putamen 9360.3± 85.8 9162.3± 260.9 9398.9± 89.1
Nucleus accumbens 860.0± 16.0 807.6± 40.41 870.3± 17.3
Globus pallidus⁎ 3264.5± 28.3 3130.7± 71.1 3290.6± 30.4
Total brain tissue volume, mm3
(gray, white, cerebrospinal ﬂuid)
1,429,104.0± 11,545.0 1,424,036.1± 32,289.1 1,430,092.6± 12,338.1
Note. NCEP=National Cholesterol Education Program; BP=blood pressure;mmHg=millimeters ofmercury; BMI=bodymass index; HDL=high-density lipoprotein; PHQ-9=9-item
Patient Health Questionnaire; Verbal IQ= Estimated Verbal IQ score from the North American Adult Reading Test (Blair and Spreen, 1989).
Values are mean± standard error of the mean, unless indicated otherwise.
a Median (interquartile range).
⁎ Signiﬁcant group difference between presence and absence of the MetS, p b 0.05.
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by sex and age [50,51] in addition to smoking relapse [52]. Finally,
depressive symptoms show sex, race, and age differences [53–55].
2.6. Statistical analyses
2.6.1. Demographic and cardio-metabolic variables
We used descriptive statistics to characterize participants with
and without the MetS on age, years of education, smoking status, body
mass index (BMI), and MetS components. Speciﬁcally, differences in
demographic and cardio-metabolic risk factors as a function of presence
of the MetS were analyzed using t-tests for continuous variables and
chi-square test for categorical variables (see Table 1).
2.6.2. Volumetric variables
Several regression models were used to determine the effect of the
MetS on basal ganglia volumes, adjusting for age, sex, race, education,
smoking status, and total brain volume as covariates. The relationships
between the MetS and volumes in basal ganglia ROIs were assessed
ﬁrst by regressing a variable coding the presence/absence of the MetS
on standardized (mean = 0; standard deviation = 1) average bilateral
volumes for the nucleus accumbens, caudate nucleus, putamen, and
globus pallidus in a single logistic regression model. Accordingly, the
results reﬂect unique relationships between the MetS and basal ganglia
volumes in a single model, as opposed to relationships revealed in
separate models for each basal ganglia ROI, which would inﬂate type I
error.We also conducted an additional logistic regressionmodelwhereby
the presence/absence of the MetS was based on individuals meeting
criteria for MetS (i.e., 3 or more criteria) that were compared against
a subset of individuals meeting no criteria for any MetS component.
Next, we examined associations between basal ganglia volumes and the
number of MetS criteria met across the full sample of 147 participants
in a similarly structured negative binomial model — regressing the
number of MetS criteria met (i.e., criteria counts) on basal ganglia
volumes. Hence, for these negative binomial models, the number of
MetS criteria met (ranging from 0–5) was regressed on basal gangliabrain volumes together in one model with covariate adjustment. We
also regressed a modiﬁed number of MetS criteria met (ranging from 0–
3+) variable on basal ganglia volume to ensure that the few individuals
that met criteria for 4 or 5 components did not inﬂuence the results.
Exploratory logistic regression analyses were also performed on the
individual components of theMetS (i.e., lowHDL cholesterol or elevated
blood pressure, plasma glucose, triglycerides, or waist circumference)
by regressing the presence/absence of each MetS component on basal
ganglia volumes to determine which components were most closely
related to basal ganglia volumes. Similar exploratory analyses with
linear regression models were also performed on continuous measures
of each syndrome component. Logarithmic transformations were
applied to triglyceride values to correct distributional skew, and outliers
(i.e., 3 SD above or below the respective means) were removed from
blood glucose (n=4) and HDL cholesterol distributions (n=1).
An alpha of 0.05was used for all tests of statistical signiﬁcance, while
an alpha within the range of 0.06–0.10 was taken as a trend. To aid
interpretation and clearly convey effect sizes, positive logistic regression
coefﬁcients are presented alongside odds ratios (OR; the exponentiated
regression coefﬁcient, eB), and negative logistic regression coefﬁcients
alongside inverse odds ratios (IOR; the inverse of the exponentiated
regression coefﬁcient, 1/eB). Negative binomial results are presented
alongside the exponentiated regression coefﬁcients, and these can be
interpreted as the change in number of criteria met per unit change
in predictor of interest. All analyses were conducted using SPSS
version 20.
2.6.3. Depression variables
Similar regression models were used to test whether depressive
symptoms were associated with the MetS (i.e., presence/absence,
number of criteriamet). Hence, logistic and negative binomial regression
models were used to predict the presence/absence of the MetS and
the number of criteria (i.e., 0–5, 0–3+) as a function of depressive
symptoms, adjusting for age, sex, race, smoking, and education. In light
of prior reports linking MDD and depressive symptoms to altered basal
ganglia morphology [21,23–29], we also examined the relationship
Fig. 1. Panels A and B plot unadjusted globus pallidus volume as a function of absence or presence of themetabolic syndrome and the number of metabolic syndrome criteria met. Panels
C andD plot globus pallidus volumes that are adjusted formodel covariates (age, gender, race, smoking status, and education, aswell as graymatter, whitematter and cerebral spinal ﬂuid
volumes). Signiﬁcant group differences in globus pallidus volumewere explainedby individualswith themetabolic syndrome showing smaller pallidal volume. The shaded data points are
the three outliers identiﬁed across both the pallidal and putamen volumes.
Fig. 2. Scatterplot of the association between the volume of globus pallidus (adjusted for
age, gender, race, smoking status, education, and total brain tissue volume) and PHQ-9
depression scores.
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linear regression models, whereby PHQ-9 scores were regressed on
basal ganglia ROI volumes with covariate adjustment.
2.6.4. Exploratory mediation
To test whether basal ganglia volumes might meditate observed
associations between the MetS and depressive symptoms, we used the
product-of-coefﬁcients strategy that tests the signiﬁcance of the indirect
effect (i.e., the path through a proposed mediator) by bootstrapping the
product of the effect of the independent variable on the mediator (path
a), and the effect of the mediator on the dependent variable accounting
for the effect of the independent variable (path b). However, the sampling
distribution of the indirect effect that is determined through the ab
product of coefﬁcients is subject to violations of normality when the
possibility of mediation is present [56]. Hence, Preacher and Hayes [57]
recommend using a bootstrapping approach whereby 5000 estimates of
ab are used to calculate conﬁdence intervals (CIs) and standard errors
around the indirect effect. This bootstrappedmediation analysis approach
was performed with the INDIRECT macro designed for SPSS [57].
In these analyses, we computed two mediation models with the
INDIRECT macro for each operational deﬁnition of the MetS under
study (i.e., presence/absence, number of criteria met). The presence of
the MetS or the number of MetS criteria met served as independent
variables in separate models, depressive symptoms as measured
2 In secondary analyses, similar models indicated that the presence of MetS was
independently related to left (B = −0.66, SE = 0.31, IOR = 1.94, p = 0.03) and right
(B=−0.71, SE=0.32, IOR=2.04, p=0.02) globus pallidus volume after adjusting for
demographic and health-related factors, and total brain tissue volume. Further, the
number of MetS criteria met was also associated with left (B = −0.18, SE = 0.10,
eB=0.84, p=0.06) and right (B=−0.23, SE=0.10, eB=0.79, p=0.02) pallidal volume,
althoughmarginallywith left regions. Again, the correlation between right and left globus
pallidus volumewas strong (r=0.69, pb0.01)which validated the use of average bilateral
globus pallidus volume.Nonetheless, laterality effects did not appear to drive the observed
volumetric associations.
Fig. 3. The association between number of metabolic syndrome (MetS) components
and PHQ-9 depression score. Subjects with three, four, and ﬁve MetS components
were combined.
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volume(s) served as mediators. Age, sex, education, smoking status,
race, and total brain volume were included as confounding covariates.
Speciﬁc to modeling the indirect effect for number of criteria met, we
ﬁrst constructed k-1 dummy variables, with k being the number of
possible criteria met. To model the indirect effect for number of criteria
met, we ﬁrst constructed k-1 dummy variables, with k being the
number of possible number of criteria met. Next, each dummy variable
was entered as an independent variable while the others were entered
as covariates. This provided a test of the indirect effect of each category
relative to reference category (i.e., meeting zero MetS criteria) in our
dummy-coding scheme.
3. Results
3.1. Prevalence of MetS
There were 24 participants who met criteria for having the MetS
and 123 subjects who did not. Thus, the prevalence of the MetS in
this otherwise healthy and un-medicated sample was 16.3%, which is
consistent with expected rates of the MetS demonstrated in national
samples and similar community samples recruited from Allegheny
County, Pennsylvania [49,58,59]. Table 1 shows descriptive statistics
for the participants' demographic and other characteristics.
Among the 24with theMetS, 18met three criteria, 4met four criteria,
and 2met ﬁve criteria. Further, among these individuals meeting criteria
for the MetS, the following frequencies were observed across syndrome
components: lowHDL cholesterol (n=23), elevatedwaist circumference
(n=21), elevated systolic (n=13) and diastolic (n=6) blood pressure,
elevated triglycerides (n= 12), and elevated fasting glucose (n = 10).
Among the 123 without the MetS, 51 met zero criteria, 44 met one
criterion, and 28 met two criteria. The following frequencies were
observed across syndrome components among those who were without
the MetS: low HDL cholesterol (n= 40), elevated waist circumference
(n=25), elevated systolic (n=15) anddiastolic (n=12) bloodpressure,
elevated triglycerides (n=7), and elevated fasting glucose (n=7).
3.2. MetS and basal ganglia volume
The presence of the MetS was associated with reduced gray matter
volumewithin the basal ganglia. Hence, after accounting for demographic
and health-related variables, reduced gray matter volume in the globus
pallidus in particular was associated with an increased odds of having
the MetS (B =−0.83, SE= 0.37, IOR = 2.30, p = 0.03). Speciﬁcally,
a decrease of one standard deviation in globus pallidus volume wasassociated with 2.30 times increased odds of meeting criteria for the
MetS. Because more than half of the individuals without the MetS
met criteria for some MetS components (i.e., 72/123 met criteria for
one or two components; see Section 3.1), we ran an additional logistic
regression model comparing individuals with the MetS to a subset
of individuals who did not meet criteria for any MetS component. The
group differences were still present, such that reduced pallidal gray
matter volumewas speciﬁcally associatedwith a greater odds of having
the MetS (B = −0.93, SE = 0.48, IOR = 2.54, p = 0.05). Similarly,
negative binomial models revealed that only globus pallidus volume
covaried inversely with the number of MetS criteria met while
simultaneously accounting for all other basal ganglia ROI volumes
(B=−0.27, SE=0.11, eB=0.76, p=0.02), indicating that one standard
deviation decrease in globus pallidus volume was associated with 76%
increase in the number of MetS criterion met.2 By contrast, neither the
presence of the MetS nor the number of MetS criteria met covaried
positively or negatively with the volume of other basal ganglia ROIs;
namely, the caudate, putamen, and nucleus accumbens (ps N 0.34).
Fig. 1 shows the associations of pallidal volume to the presence of the
MetS and the number of MetS criteria met.
With respect to individual MetS components, reduced globus
pallidus volume was associated with elevated waist circumference
(B=−0.78, SE=0.32, IOR=2.18, p=0.02) and low HDL cholesterol
(B=−0.56, SE=0.27, IOR=1.75, p=0.04) while there was a trend
for elevated fasting glucose (B = −1.15, SE = 0.52, IOR = 3.15,
p= 0.10). And although gray matter volume in the putamen did not
covary with either the presence of the MetS or the number of MetS
criteria met, reduced putamen volume was associated with elevated
blood pressure (B=−0.74, SE=0.35, IOR=2.10, p=0.04). Additional
analyses also examined the association between continuous cardio-
metabolic parameters deﬁning the syndrome and basal ganglia volume.
After adjusting for demographic and health-related factors, continuous
measures of waist circumference (B=−0.12, t=−1.88, p=0.06) and
HDL cholesterol (B = 0.12, t = 1.82, p = 0.07) showed marginal
associations with pallidal volume.3.3. MetS and depressive symptoms
Depressive symptoms were positively associated with the number
of MetS criteria met (Fig. 3). Hence, after adjusting for age, sex, race,
smoking, and education, greater severity in depressive symptoms was
associated with meeting more MetS criteria (B = 0.10, SE = 0.05,
eB=1.11, p=0.03). In an additional model wherein number of criteria
met was deﬁned as 0–3+, the dose–response relationship between
number of criteria met and depressive symptoms trended toward
signiﬁcance (B = 0.09; SE = 0.05, eB = 1.09; p = 0.07). Contrary
to prior research [60], however, we did not observe a signiﬁcant
association between presence/absence of the MetS and depressive
symptoms, even in unadjusted analyses (ps≥0.16).3.4. Basal ganglia volume and depressive symptoms
Reduced globus pallidus volume covaried with higher depressive
symptoms (B=−0.16, t=−2.52, p=0.01), after adjusting for total
brain tissue volume (Fig. 2). This association between depressive
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demographic and health-related covariates (p=0.04).
3.5. Mediation testing
The signiﬁcant pattern of results between (i) number of MetS
criteria met and globus pallidus volume and (ii) globus pallidus volume
and depressive symptoms indicates that variation in pallidal gray
matter volume may represent a candidate mediator linking number of
MetS criteria met and depressive symptoms. Despite the absence of a
total effect between presence of the MetS and depressive symptoms,
we did test the hypothesis of a possible indirect effect through globus
pallidus volume in accordance with prior recommendations regarding
mediation testing [61]. We found a signiﬁcant indirect effect with
respect to presence/absence of the MetS and depressive symptoms
through globus pallidus volume (ab indirect effect = 0.130;
SE=0.094; 95% CI = 0.0041, 0.398; p b 0.05). Similarly, we found
that association of number of syndrome criteria met on depressive
symptoms was mediated by globus pallidus volume (ab indirect
effect= 0.147, SE=0.108; CI= 0.0090, 0.4862 p b 0.05). This indirect
effect was speciﬁc to meeting three syndrome criteria. Based on the
direction of the paths, this mediation effect indicates that individuals
with the MetS and/or meeting criteria for three MetS components
may exhibit increased depressive symptoms as statistically mediated
by decreases in pallidal regions of the basal ganglia.
3.6. Ancillary analyses
We identiﬁed 3 potential outlier cases (see Fig. 1) exhibiting pallidal
and putamen gray matter volumes that were 3 SD above the mean
of their respective brain volume distributions. Ancillary analyses were
conducted to determine whether removal of these outliers would
inﬂuence our observed results regarding the signiﬁcant MetS-pallidal
or pallidal-depressive symptom associations. Removal of these outliers
did not alter any of the respective associations between the MetS,
globus pallidus volume, and depressive symptoms; graymatter volume
in the putamen was not associated with MetS or depressive symptoms
after outlier adjustment. Hence, our reported ﬁndings persisted after
accounting for the inﬂuence of these cases.
4. Discussion
The ﬁrst novel ﬁnding of this study was that individuals with
the MetS showed reduced gray matter volume in the globus pallidus,
independent of demographic and health-related variables. Second,
individuals meeting more MetS criteria showed a graded reduction in
globus pallidus volume — suggesting a dose–response association,
rather than a threshold effect of meeting binaryMetS diagnostic criteria
(i.e., presence vs. absence). However, neither the presence of the MetS
nor the number of MetS criteria met associated signiﬁcantly with gray
matter volume in other basal ganglia regions. Third, as consistent with
prior work [62], we found that individuals meeting more MetS criteria
reported more depressive symptoms. Fourth, reduced globus pallidus
volume mediated the association between meeting more MetS criteria
and depressive symptoms. Finally, we found an indirect mediation
effect of the MetS (i.e., presence, absence) on depressive symptoms
through reduced globus pallidus volume, even though we observed no
statistically signiﬁcant total effect of theMetS on depressive symptoms.
Taken together, there appears to be regional speciﬁcity within the basal
ganglia – namely in the globus pallidus – with respect to volumetric
reductions that are associated with the MetS and meeting more MetS
criteria among otherwise healthy individuals. It is possible that these
volumetric changes in the globus pallidus may correspond to a neural
correlate that is common to the MetS and depressive symptomatology.
However, the causal directions of association between the MetS,depressive symptomatology, and globus pallidus volume are unclear
because of the correlational design of the present study.
Despite this design limitation, our novel ﬁnding of an inverse
association between the MetS and pallidal volume appears consistent
with prior animal and human evidence linking functional alterations
within the basal ganglia to impairments in metabolism and energy
balance [63]. This ﬁnding also appears consistent with those showing
that individual components and correlates of the MetS, including
adiposity [18], impaired fasting glucose [18], and insulin resistance
[19], are associated with structural changes within the pallidal region
of the basal ganglia. This ﬁnding also adds to an emerging literature
indicating theMetS as a whole, as opposed to its individual components,
relates to adverse brain changes and associated impairments in cognitive
functions [17]. We note, however, that although we did not ﬁnd
adiposity or glucose associations with the volumes of other basal ganglia
regions (e.g., putamen; [20]), other studies have reported similar null
associations [64–66]. By contrast, our ﬁndings did replicate previous
work [18], insofar as we found that both high fasting glucose and central
adiposity (elevated waist circumference) covaried with reduced globus
pallidus volume. Thus, in light of our ﬁndings and prior work, it may be
that the link between theMetS and globus pallidus volumemore closely
reﬂects the associations of adiposity and glucose dysregulation with this
region, as compared with other basal ganglia regions and other features
and correlates of the MetS [67]. This interpretation is consistent with
cumulative evidence that adiposity and glucose dysregulation are likely
to be key etiological factors in the development of the MetS [39].
However, we cannot rule out the possibility that the MetS association
with reduced globus pallidus volume is mediated by factors other than
glucose dysregulation or central adiposity (e.g., systemic inﬂammatory
mechanisms). Although, it is noteworthy that we found individuals
meeting more MetS criteria exhibited a graded reduction in the gray
matter volume of the globus pallidus, which suggests that (i) the other
syndrome components are also linked to structural changes in this
region, and (ii) the aggregate clustering of multiple MetS components
exhibited a dose–response or graded association with the gray matter
volume of this region, above-and-beyond just the presence of adiposity,
glucose elevations, or other isolated MetS components per se. The latter
observation appears consistent with work showing that the clustering
of cardio-metabolic risk factors accounts for unique variation in MRI
indicators of gross brain atrophy [68,69], and it adds to this work by
showing an apparently speciﬁc neural correlate of the MetS (reduced
globus pallidus volume) that is still observed after accounting for gross
or total brain tissue volume.
The potential functional implications of reduced gray matter volume
in the globus pallidus may relate to the role of this region in regulating
physiologic processes relevant to the development of the MetS [13].
For instance, neurochemical and animal lesion studies suggest an
inﬂuence of the globus pallidus on glucosemetabolism [70], with pallidal
lesions inducing hyperglycemia in rats [71]. More recent work has also
shown that lesions to ventral regions of the pallidum lead to elevated
glucose levels coupled with impaired glucose control following a reg-
ulatory challenge [72]. Critically, such pallidal lesions produce hyper-
glycemic levels that are enduring and comparable to pre-diabetic states
in humans, states that are engendered by the MetS. Additional human
case study evidence has also shown that a patient with lesions to the
globus pallidus gained 20-lbs [29]. Although speculative, it may be that
the gray matter changes in the globus pallidus linked to the MetS and,
more speciﬁcally, impaired fasting glucose and adiposity might reﬂect
alterations in energy balance functions served by the globus pallidus
[73].
We also found that reduced pallidal volume was associated with
more depressive symptomatology, which agrees with prior work
[14,28]. Existing models of depression indicate that the globus pallidus
and other basal ganglia regions are components of prefrontal and limbic
circuits important for goal-directed behaviors and executive cognitive
control processes that support emotion and mood regulation [74].
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thalamo-cortical stimulation of prefrontal areas that mediate the reg-
ulation of negative affect [74,75]. Thus, the anatomical connections of
the globus pallidus support the possibility that structural or volumetric
changes in this region may relate to the pathophysiology of depression
or depression risk by affecting emotion regulation functions supported
by prefrontal and limbic circuits [75]. And here, our results appear to
extend previous clinical ﬁndings by demonstrating that depressive-
related variation in the gray matter volume of the globus pallidus
might be best conceptualized along on a continuum that extends to
otherwise healthy individuals. In view of such a conceptualization, it
may be that volumetric and other features of basal ganglia morphology
could reﬂect a so-called endophenotype associated with vulnerability
to or risk for depression. In support of this possibility, two recent studies
have proposed that depression vulnerability among otherwise healthy
individuals might relate to volumetric reductions in the basal ganglia
[76,77]. However, further research bearing on this issue is needed to
determine whether the volumetric or other morphological changes in
the pallidum emerge before or after the onset of depressive symptoms —
especially in the context of comorbid metabolic dysregulation and MetS
development [22].
In this context, it is noteworthy that in the present study individuals
exhibiting more depressive symptoms also met more MetS criteria,
which agrees with prior work on otherwise healthy adults [62,78,79].
Given that theMetS involves diverse physiological changes (e.g., systemic
inﬂammatory states) that are associated with and implicated in the
symptomatic expression of depression, it appears reasonable to expect
that depressive symptoms would be more prevalent among individuals
meeting more MetS criteria [80]. Our mediation ﬁndings extend
prior ﬁndings linking peripheral physiological changes associated with
the MetS and depressive symptomatology by identifying a potential
mediating factor: reduced globus pallidus volume. As noted previously,
this observation is consistent with prior ﬁndings and speculations
that the MetS and depressive symptoms may share common patho-
physiological features [22], including alterations in central neuro-
transmitter systems that covary with metabolic dysregulation [58,59]
and risk for depressive symptoms [81], as well as volume reductions
in basal ganglia regions [74,82]. Again, however, the causal directions of
associations and temporal ordering of depressive symptoms, volumetric
changes, and depressive symptoms need to be tested in future longit-
udinal research.
In closing, there are several remaining study limitations and speciﬁc
future directions that should be acknowledged. First, our present
study does not permit inferences regarding the mechanisms that link
the MetS to globus pallidus volume. Second, although our ﬁndings
were speciﬁc to the globus pallidus, previous studies have implicated
volumetric and white matter changes in medial temporal and other
regions as a possible neural correlates of the MetS among adolescents
[83]. Thus, future studies on adults should employ multimodal and
voxel-wise methods that permit an examination of such changes in
regions outside of the basal ganglia. This suggestion is reinforced by
ﬁndings showing that individual components of the MetS covary with
gray matter changes in the regions of the frontal and temporal lobes
[18–20,64,84,85]. Third, our exclusion criteria likely truncated variability
in depressive symptoms to a range that is more restricted than that
observed in prior studies of the MetS and depressive symptoms [60].
In extension, the use of more structured instruments and interviews
to systematically assess depressive symptoms may better capture
sub-clinical variation in self-reported symptoms in otherwise healthy
community samples such as ours. Finally, an unmeasured third-factor
explanation, such as a shared genetic or heritable factor, may have
accounted for the observed co-expression of the MetS, globus pallidus
volume reductions, and depressive symptoms, which may not be
functionally or causally related. Thus, longitudinal study designs that
incorporate imaging assessments, as well as more comprehensive
measures of mood-related symptoms, energy metabolism, and healthbehaviors (e.g., food intake and physical activity) are needed to extend
the present ﬁndings to better understand the mechanisms and func-
tional implications of the associations between the MetS, depressive
symptoms, and gray matter volume changes in the basal ganglia.
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